Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free BDMD Stock Alerts

Baird Medical Investment (BDMD) Financials

Baird Medical Investment logo
$1.06 -0.02 (-1.40%)
As of 01:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Baird Medical Investment

Annual Income Statements for Baird Medical Investment

This table shows Baird Medical Investment's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 13 11 12 -27
Consolidated Net Income / (Loss)		 13 11 13 -28
Net Income / (Loss) Continuing Operations		 13 11 13 -28
Total Pre-Tax Income 		15 12 14 -26
Total Operating Income		 14 12 15 -26
Total Gross Profit		 28 27 33 19
Total Revenue		 35 31 37 23
Operating Revenue		 35 31 37 23
Total Cost of Revenue		 7.05 4.23 4.38 3.65
Operating Cost of Revenue		 7.05 4.23 4.38 3.65
Total Operating Expenses		 14 15 17 45
Selling, General & Admin Expense		 6.96 8.55 7.10 14
Marketing Expense		 3.59 2.55 4.06 10
Research & Development Expense		 3.86 4.27 6.17 20
Total Other Income / (Expense), net		 0.89 0.50 -1.23 -0.74
Interest & Investment Income		 1.38 -0.28 -0.58 -0.64
Other Income / (Expense), net		 -0.19 0.78 -0.65 -0.10
Income Tax Expense		 1.75 1.70 1.49 1.17
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.21 0.11 0.14 -0.51
Basic Earnings per Share		 $0.49 $0.51 $0.57 ($0.98)
Weighted Average Basic Shares Outstanding		 25.56M 20.59M 21.83M 27.79M
Diluted Earnings per Share		 $0.49 $0.51 $0.57 ($0.98)
Weighted Average Diluted Shares Outstanding		 25.56M 20.59M 21.83M 27.79M
Weighted Average Basic & Diluted Shares Outstanding		 - - 35.73M 40.98M

Quarterly Income Statements for Baird Medical Investment

No quarterly income statements for Baird Medical Investment are available.

Annual Cash Flow Statements for Baird Medical Investment

This table details how cash moves in and out of Baird Medical Investment's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.32 -0.20 1.46 -2.40
Net Cash From Operating Activities		 0.49 -1.02 -6.31 -1.34
Net Cash From Continuing Operating Activities		 0.49 -1.02 -6.31 -1.34
Net Income / (Loss) Continuing Operations		 13 11 13 -28
Consolidated Net Income / (Loss)		 13 11 13 -28
Depreciation Expense		 0.92 1.01 1.14 1.10
Amortization Expense		 0.55 0.36 0.37 0.31
Non-Cash Adjustments To Reconcile Net Income		 -0.40 2.17 1.56 18
Changes in Operating Assets and Liabilities, net		 -13 -15 -22 6.77
Net Cash From Investing Activities		 -5.92 -2.65 -2.47 -0.04
Net Cash From Continuing Investing Activities		 -5.92 -2.65 -2.47 -0.04
Purchase of Property, Plant & Equipment		 -5.91 -2.64 -2.85 -0.04
Purchase of Investments		 - -0.01 0.00 0.00
Sale and/or Maturity of Investments		 - 0.00 0.39 0.00
Net Cash From Financing Activities		 4.41 3.48 10 -1.39
Net Cash From Continuing Financing Activities		 4.41 3.48 10 -1.39
Repayment of Debt		 -4.61 -7.68 -12 -20
Issuance of Debt		 9.07 12 22 18
Issuance of Preferred Equity		 0.00 0.00 2.90 0.00
Other Financing Activities, net		 -0.05 -1.00 -2.88 0.76
Effect of Exchange Rate Changes		 -0.30 -0.00 -0.09 0.38
Cash Interest Paid		 0.24 0.29 0.58 0.74
Cash Income Taxes Paid		 1.44 2.64 1.84 0.84

Quarterly Cash Flow Statements for Baird Medical Investment

No quarterly cash flow statements for Baird Medical Investment are available.

Annual Balance Sheets for Baird Medical Investment

This table presents Baird Medical Investment's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 57 78 70
Total Current Assets		 40 61 55
Cash & Equivalents		 1.51 2.97 0.18
Restricted Cash		 - 0.00 0.39
Note & Lease Receivable		 0.00 0.00 0.00
Accounts Receivable		 31 47 43
Inventories, net		 1.14 1.30 1.09
Prepaid Expenses		 5.81 10 11
Other Current Assets		 0.12 0.30 0.24
Plant, Property, & Equipment, net		 6.14 7.14 6.37
Total Noncurrent Assets		 10 9.41 8.36
Goodwill		 0.06 0.06 0.06
Intangible Assets		 0.03 0.02 0.01
Noncurrent Deferred & Refundable Income Taxes		 0.81 0.71 0.76
Other Noncurrent Operating Assets		 9.59 8.62 7.53
Total Liabilities & Shareholders' Equity		 57 78 70
Total Liabilities		 21 38 38
Total Current Liabilities		 19 35 32
Short-Term Debt		 8.98 17 13
Accounts Payable		 0.55 1.25 1.81
Accrued Expenses		 3.04 7.86 7.91
Current Deferred & Payable Income Tax Liabilities		 0.86 2.92 3.11
Current Employee Benefit Liabilities		 0.75 0.80 0.68
Other Current Liabilities		 4.79 4.76 5.80
Total Noncurrent Liabilities		 2.03 3.58 6.11
Long-Term Debt		 1.61 3.44 6.09
Other Noncurrent Operating Liabilities		 0.41 0.14 0.03
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 36 40 31
Total Preferred & Common Equity		 36 40 31
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 36 40 31
Common Stock		 19 11 29
Retained Earnings		 14 27 -0.52
Accumulated Other Comprehensive Income / (Loss)		 -2.01 -3.14 -1.37
Other Equity Adjustments		 4.51 4.59 4.59
Noncontrolling Interest		 -0.04 0.10 -0.14

Quarterly Balance Sheets for Baird Medical Investment

No quarterly balance sheets for Baird Medical Investment are available.

Annual Metrics And Ratios for Baird Medical Investment

This table displays calculated financial ratios and metrics derived from Baird Medical Investment's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 35,728,625.00 40,979,382.00
DEI Adjusted Shares Outstanding		 0.00 0.00 35,728,625.00 40,979,382.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.35 -0.67
Growth Metrics		 - - - -
Revenue Growth		 0.00% -10.35% 17.74% -39.15%
EBITDA Growth		 0.00% -11.30% 22.29% -250.36%
EBIT Growth		 0.00% -11.80% 23.73% -275.48%
NOPAT Growth		 0.00% -14.70% 33.89% -231.00%
Net Income Growth		 0.00% -16.57% 18.20% -318.61%
EPS Growth		 0.00% 4.08% 11.76% -271.93%
Operating Cash Flow Growth		 0.00% -309.88% -518.95% 78.71%
Free Cash Flow Firm Growth		 0.00% 0.00% 103.54% -957.05%
Invested Capital Growth		 0.00% 0.00% 27.84% -13.02%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 79.90% 86.56% 88.16% 83.79%
EBITDA Margin		 42.48% 42.03% 43.66% -107.89%
Operating Margin		 38.85% 37.71% 41.35% -113.73%
EBIT Margin		 38.29% 37.67% 39.59% -114.17%
Profit (Net Income) Margin		 36.41% 33.88% 34.01% -122.20%
Tax Burden Percent		 87.97% 86.24% 89.43% 104.42%
Interest Burden Percent		 108.07% 104.28% 96.07% 102.50%
Effective Tax Rate		 12.03% 13.76% 10.57% 0.00%
Return on Invested Capital (ROIC)		 0.00% 45.67% 26.84% -33.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 55.11% 18.58% -86.70%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 14.03% 6.55% -44.09%
Return on Equity (ROE)		 0.00% 59.70% 33.39% -77.60%
Cash Return on Invested Capital (CROIC)		 0.00% -154.33% 2.40% -19.59%
Operating Return on Assets (OROA)		 0.00% 20.90% 21.78% -34.85%
Return on Assets (ROA)		 0.00% 18.79% 18.71% -37.30%
Return on Common Equity (ROCE)		 0.00% 59.77% 33.36% -77.64%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 12 10 14 -18
NOPAT Margin		 34.17% 32.52% 36.98% -79.61%
Net Nonoperating Expense Percent (NNEP)		 0.00% -9.44% 8.26% 53.19%
Return On Investment Capital (ROIC_SIMPLE)		 - 22.09% 22.74% -35.61%
Cost of Revenue to Revenue		 20.10% 13.44% 11.84% 16.21%
SG&A Expenses to Revenue		 19.84% 27.17% 19.18% 62.65%
R&D to Revenue		 11.00% 13.59% 16.67% 89.32%
Operating Expenses to Revenue		 41.05% 48.86% 46.81% 197.52%
Earnings before Interest and Taxes (EBIT)		 13 12 15 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 15 13 16 -24
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.18 1.21
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.19 1.21
Price to Revenue (P/Rev)		 0.00 0.00 4.48 1.68
Price to Earnings (P/E)		 0.00 0.00 13.32 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 7.51% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 3.20 1.13
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 4.95 2.50
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 11.35 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 12.51 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 13.40 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 149.94 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.30 0.52 0.61
Long-Term Debt to Equity		 0.00 0.05 0.09 0.19
Financial Leverage		 0.00 0.25 0.35 0.51
Leverage Ratio		 0.00 1.59 1.78 2.08
Compound Leverage Factor		 0.00 1.66 1.71 2.13
Debt to Total Capital		 0.00% 22.89% 33.99% 38.02%
Short-Term Debt to Total Capital		 0.00% 19.40% 28.28% 25.94%
Long-Term Debt to Total Capital		 0.00% 3.48% 5.72% 12.08%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -0.09% 0.17% -0.29%
Common Equity to Total Capital		 0.00% 77.21% 65.84% 62.26%
Debt to EBITDA		 0.00 0.80 1.27 -0.79
Net Debt to EBITDA		 0.00 0.69 1.08 -0.76
Long-Term Debt to EBITDA		 0.00 0.12 0.21 -0.25
Debt to NOPAT		 0.00 1.04 1.50 -1.07
Net Debt to NOPAT		 0.00 0.89 1.28 -1.04
Long-Term Debt to NOPAT		 0.00 0.16 0.25 -0.34
Altman Z-Score		 0.00 0.00 4.59 0.07
Noncontrolling Interest Sharing Ratio		 0.00% -0.12% 0.08% -0.06%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 2.11 1.77 1.70
Quick Ratio		 0.00 1.74 1.43 1.32
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -35 1.22 -10
Operating Cash Flow to CapEx		 8.27% -38.66% -221.23% -3,176.25%
Free Cash Flow to Firm to Interest Expense		 0.00 -121.59 2.12 -14.22
Operating Cash Flow to Interest Expense		 1.62 -3.59 -10.95 -1.82
Operating Cash Flow Less CapEx to Interest Expense		 -18.01 -12.87 -15.90 -1.88
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.55 0.55 0.31
Accounts Receivable Turnover		 0.00 1.00 0.95 0.51
Inventory Turnover		 0.00 3.70 3.59 3.07
Fixed Asset Turnover		 0.00 5.12 5.58 3.34
Accounts Payable Turnover		 0.00 7.68 4.86 2.39
Days Sales Outstanding (DSO)		 0.00 365.42 384.70 721.60
Days Inventory Outstanding (DIO)		 0.00 98.65 101.55 119.01
Days Payable Outstanding (DPO)		 0.00 47.50 75.06 152.75
Cash Conversion Cycle (CCC)		 0.00 416.57 411.20 687.86
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 45 57 50
Invested Capital Turnover		 0.00 1.40 0.73 0.42
Increase / (Decrease) in Invested Capital		 0.00 45 12 -7.45
Enterprise Value (EV)		 0.00 0.00 183 56
Market Capitalization		 0.00 0.00 166 38
Book Value per Share		 $0.00 $1.74 $1.82 $0.88
Tangible Book Value per Share		 $0.00 $1.73 $1.81 $0.88
Total Capital		 0.00 46 60 50
Total Debt		 0.00 11 20 19
Total Long-Term Debt		 0.00 1.61 3.44 6.09
Net Debt		 0.00 9.09 18 19
Capital Expenditures (CapEx)		 5.88 2.64 2.85 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 29 41 35
Debt-free Net Working Capital (DFNWC)		 0.00 30 44 36
Net Working Capital (NWC)		 0.00 21 27 23
Net Nonoperating Expense (NNE)		 -0.78 -0.43 1.10 9.60
Net Nonoperating Obligations (NNO)		 0.00 9.09 18 19
Total Depreciation and Amortization (D&A)		 1.47 1.37 1.51 1.42
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 90.85% 110.31% 155.78%
Debt-free Net Working Capital to Revenue		 0.00% 95.66% 118.33% 158.29%
Net Working Capital to Revenue		 0.00% 67.10% 72.34% 100.31%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.49 ($0.98)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 25.56M 27.79M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.49 ($0.98)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 25.63M 27.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 35.73M 40.98M
Normalized Net Operating Profit after Tax (NOPAT)		 12 10 14 -18
Normalized NOPAT Margin		 34.17% 32.52% 36.98% -79.61%
Pre Tax Income Margin		 41.38% 39.29% 38.04% -117.03%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 44.90 41.69 25.44 -34.90
NOPAT to Interest Expense		 40.07 35.98 23.76 -24.33
EBIT Less CapEx to Interest Expense		 25.26 32.41 20.49 -34.95
NOPAT Less CapEx to Interest Expense		 20.43 26.70 18.81 -24.39
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Baird Medical Investment

No quarterly metrics and ratios for Baird Medical Investment are available.


Financials Breakdown Chart

Baird Medical Investment Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Baird Medical Investment's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Baird Medical Investment's net income appears to be on a downward trend, with a most recent value of -$27.54 million in 2025, falling from $12.77 million in 2022. The previous period was $12.60 million in 2024. Find out what analysts predict for Baird Medical Investment in the coming months.

Baird Medical Investment's total operating income in 2025 was -$25.63 million, based on the following breakdown:
  • Total Gross Profit: $18.88 million
  • Total Operating Expenses: $44.51 million

Over the last 3 years, Baird Medical Investment's total revenue changed from $35.09 million in 2022 to $22.54 million in 2025, a change of -35.8%.

Baird Medical Investment's total liabilities were at $38.48 million at the end of 2025, a 0.7% increase from 2024, and a 83.2% increase since 2023.

In the past 2 years, Baird Medical Investment's cash and equivalents has ranged from $178.32 thousand in 2025 to $2.97 million in 2024, and is currently $178.32 thousand as of their latest financial filing in 2025.

Over the last 3 years, Baird Medical Investment's book value per share changed from 0.00 in 2022 to 0.88 in 2025, a change of 87.8%.


Related Companies

Financial statements for NASDAQ:BDMD last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel